Clinical Trial

Testing Experimental Schizophrenia Medication

Study Description

Study of CAD-9303 in Subjects With Schizophrenia

This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized, double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - CAD-9303

Capsules filled with CAD-9303 from 3 mg up to 1000 mg.

Drug - Placebos

Capsules

Additional Information

Official Study Title

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers

Clinical Trial ID

NCT04306146

ParticipAid ID

aQWVMd